Juvenile absence epilepsy in younger adults — patients aged 16 years and older — requires a structured first-line approach tailored to the age-related clinical context. The management pathway for this population is defined by evidence-based criteria for agent selection and initiation.
Younger adults aged 16 years and older presenting with juvenile absence epilepsy who require initiation of antiepileptic therapy.
First-line management in this age group begins with oral monotherapy, with the specific agent chosen according to Level C evidence and the patient's individual clinical profile. The full protocol specifies which agents qualify, how selection is guided, and the criteria that apply.
Younger adults (16 to 59 years of age)
Treatment should begin with monotherapy.
Level C: carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid
View source ↗